B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Publication | Open Access

DOI Full Paper Access

Citations

References

2007

Year

Thomas J. Lynch, Taral Patel, Luke Dreisbach, Michael McCleod, W. Heim, Hermann Robert, Paschold Eugene, Virginie Pautret, Martin R. Weber, Donald Woytowitz

Journal of Thoracic Oncology

MedicinePathologyTaxane/carboplatin Versus Taxane/carboplatinBronchial NeoplasmFirst-line TreatmentCancer TreatmentOncologyRadiation OncologyLung Cancer